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Background: Familial hypercholesterolemia (FH) is an autosomal-dominant hereditary 
disorder of lipid metabolism that causes lifelong exposure to increased LDL levels 
resulting in premature coronary heart disease and, if untreated, death. Recent studies 
have shown its prevalence to be higher than previously considered, which has import-
ant implications for the mortality and morbidity of associated cardiovascular disease 
(CVD). Several clinical tools are used worldwide to help physicians diagnose FH, but 
nevertheless most patients remain undetected. This systematic review of guidelines aims 
to assess the role of genetic testing in the screening, diagnosis, and management of 
patients affected by heterozygous or homozygous FH and to identify related health-care 
pathways.
methods: We performed a systematic review of the literature; inclusion criteria were 
English or Italian guidelines focusing on genetic testing. The guidelines were included 
and evaluated for their content and development process using the Appraisal of 
Guidelines for Research and Evaluation II instrument.
Results: Ten guidelines were considered eligible, and all were judged to be of good 
quality, with slight differences among them. The most common indications for perform-
ing genetic tests were high levels of cholesterol, or physical findings consistent with 
lipid disorder, in the subject or in the family history. Subsequent screening of family 
members was indicated when a mutation had been identified in the index patient. 
Regarding patient management, the various guidelines agreed that intensive treatment 
with lipid-lowering medications should begin as quickly as possible and that lifestyle 
modifications should be an integral part of the therapy.
conclusion: Since the early detection of affected patients is beneficial for effective 
prevention of CVD, genetic testing is particularly useful for identifying family members 
via cascade screening and for distinguishing between heterozygous and homozygous 
individuals, the latter of which require more extreme therapeutic intervention.
Keywords: familial hypercholesterolemia, systematic review, guidelines, genetic testing, cascade screening
Abbreviations: FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; CVD, cardiovascular disease; 
CHD, coronary heart disease; LDLR, low-density lipoprotein receptor; HeFH, heterozygous familial hypercholesterolemia; 
HoFH, homozygous familial hypercholesterolemia; DLCN, Dutch Lipid Clinic Network; MEDPED, Make Early Diagnosis to 
Prevent Early Death criteria; SBR, Simon Broome Register; AGREE II, Appraisal of Guidelines for Research and Evaluation II.
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iNtRODUctiON
Familial hypercholesterolemia (FH) is an autosomal-dominant 
genetic disorder of lipid metabolism which leads to markedly 
elevated plasma concentrations of low-density lipoprotein cho-
lesterol (LDL-C) (1). Long exposure to high levels of circulating 
LDL accelerates atherosclerotic cardiovascular disease (CVD) 
and especially coronary heart disease (CHD). If left untreated, 
men and women with heterozygous FH typically develop CHD 
before age of 55 and 60 years, respectively (2), while individuals 
with homozygous FH typically develop CHD before they are 
20 years old and do not survive beyond age 30 (3). In 79% of 
cases, FH is caused by mutations in the LDL receptor (LDLR) 
gene, resulting in defective synthesis, assembly, transport, and 
recycling of the LDLR or in impaired endocytosis of LDLs. 
Apolipoprotein B (APOB) helps the LDLR bind LDL, while 
proprotein convertase subtilisin/kexin type 9 (PCSK9) degrades 
the LDLR; mutations in the respective APOB and PCSK9 genes 
account for 5 and <1% of FH cases, respectively. The remaining 
15% of FH cases are either polygenic or are caused by other rare 
monogenic mutations in the APOE, SREBP2, and STAP1 genes 
(4). A very rare recessive form of FH is caused by mutation in 
the LDLRAP1 gene (5).
The majority of affected individuals are heterozygous [hete -
rozygous familial hypercholesterolemia (HeFH)] and, accord-
ing to recent studies (6–8), the prevalence of HeFH is higher 
than previously thought: it is now believed that it affects 
between 1/200 and 1/300 subjects and thus it is the most com-
mon monogenic disorder. In contrast, the global prevalence 
of homozygous individuals [homozygous familial hypercho-
lesterolemia (HoFH)] is much lower, occurring in 1 in every 
160,000–300,000 subjects (4). Homozygous patients can have 
the same mutation in both alleles of the same gene, or more 
commonly, they are compound heterozygotes with different 
mutations in each allele of the same gene, or, finally, they can 
be double heterozygotes with mutations in two different genes 
affecting LDLR function.
Identification of FH patients can be achieved by clinical 
diagnosis, by examination of personal and family history, or by 
genetic testing. The key characteristics of the disorder, which 
are elevated plasma LDL-C concentration, tendon xanthomas 
or corneal arcus, and family history of premature CHD, have 
been used to develop the most widely applied tools to support 
physicians during diagnosis. These are the Dutch Lipid Clinic 
Network (DLCN) criteria, the Make Early Diagnosis to Prevent 
Early Death (MEDPED) criteria, and the Simon Broome 
Register (SBR) criteria (9). The MEDPED criteria rely on age-
specific and family relative-specific total cholesterol levels only, 
while the DLCN and the SBR both include a number of other, 
similar criteria; nevertheless, no standardized international tools 
currently exist.
Genetic testing can confirm a clinical diagnosis or assist 
in identifying individuals whose close relatives will subse-
quently require screening; since FH is a disease inherited in 
an autosomal-dominant manner, cascade screening is a highly 
cost-effective means of identifying at-risk individuals by a process 
of systematic family tracing (10). Several types of genetic test 
are available, which adopt different approaches. The most rapid 
tests aim to identify a specific mutation in the LDLR, APOB, or 
PCSK9 genes that has already been identified in another family 
member (11). At the opposite, extreme are tests that check for 
all known and possible mutations in recognized disease genes 
[i.e., next-generation sequencing (NGS) for comprehensive 
mutation detection or in specific loci of interest] (12).
Although current DNA testing has demonstrated high levels 
of specificity and sensitivity, especially when combined with 
clinical criteria, the failure to find a mutation does not necessar-
ily exclude a diagnosis of FH (13). There is therefore a need to 
improve the early detection of FH, which is essential for effective 
reduction of the morbidity and mortality of CVD patients. This is 
particularly pertinent given the scale of the problem: it has been 
estimated that there are between 14 and 34 million individuals 
with FH worldwide (14, 15), but that less than 1% of potential 
patients have been identified in many countries (15).
Therefore, this systematic review of guidelines aims to evalu-
ate the role and importance of genetic testing in the screening, 
diagnosis, and management of FH patients and summarizes 
related health-care pathways.
metHODS
To find existing guidelines on FH diagnosis and manage-
ment, a systematic review of the literature was performed 
using the Pub Med database and Google Scholar between 
March and April 2017 with the search string (“Guidelines 
as Topic” [Mesh] OR “Practice Guidelines as Topic” 
[Mesh] OR “Guideline” [Publication Type] OR “guideline” 
OR “guidelines”) AND (“Hyperlipoproteine mia Type II” 
[Mesh] OR “Hyperlipoproteinemia Type III” [Mesh] OR 
“Familial Hypercholesterolemia”) for PubMed, and Guidelines 
and “Familial Hypercholesterolemia” for Google Scholar. In 
addi tion, the websites of the leading national and international 
scientific societies operating in the field of cardiovascular risk 
(CVR) control were searched for guidelines on FH (see Table S1 
in Supplementary Material for a list of the websites). The arti-
cles were retrieved from electronic databases and websites, and 
duplicates were removed. After screening titles, some further 
articles were excluded. The remaining articles were considered 
eligible if the guidelines focused on genetic testing and its role 
in the diagnosis, screening, and management of FH patients 
and were in English or Italian. Where multiple guidelines were 
obtained from the same scientific society, the most recent was 
retained. Two authors independently extracted results from 
the retrieved guidelines, and disagreements were resolved by 
a third author (16). Appraisal of Guidelines for Research and 
Evaluation II (AGREE II)—currently the most widely endorsed 
appraisal tool (16, 17)—was used to assess the quality of the 
guidelines by two authors independently. AGREE II consists or 
23 key items organized within 6 domains (Scope and Purpose, 
Stakeholder involvement, Rigor of Development, Clarity of 
Presentation, Applicability, and Editorial Independence). Each 
item is rated on a 7-point scale (being 1 as strongly disagree and 
7 as strongly agree) (16). PRISMA guidelines for reporting of 
systematic reviews and meta-analysis were followed (18).
FiGURe 1 | Flow diagram of the study selection process.
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ReSULtS
characteristics of the Guidelines
Overall, 10 guidelines met the inclusion criteria and were 
included in our systematic review (see Figure  1 and Table  1). 
Three guidelines were drafted by international panels (19–21), 
three by panels in the USA (9, 22, 23), and one guideline each by 
Italian (24), Belgian (25), British (26), and Taiwanese (27) panels. 
These were published between 2011 (21, 23, 25) and 2017 (22, 
27). Four guidelines (20–22, 27) declared editorial independency, 
three contained claims about conflicts of interest (9, 19, 23), and 
three did not make a declaration (24–26). According to AGREE 
II, the average overall score was 4.6, ranging from 6 (9) to 3 (24). 
The domain with the worst average percentage of agreement was 
Applicability (34.3%), followed by Rigor of Development (36.8%), 
Editorial Independence (38%), and Stakeholder Involvement 
(46.9%). The domains with higher compliance were Clarity of 
Presentation (80.2%) and Scope and Purpose (82.7%).
Genetic testing
Table 2 describes the characteristics that identify subjects requir-
ing genetic testing for FH, according to the various guidelines. Six 
guidelines (9, 19, 21, 23, 25, 26) indicate to search for mutations of 
LDL-R, APOB, and PCSK9 genes, while the others do not specify 
which detection method is recommended. One guideline (23) 
asserts that there is no need to screen the general population. In 
children, genetic analysis is indicated when cholesterol levels are 
high, according to three guidelines (19, 20, 24), although these 
guidelines differ in cutoff values and whether to take into account 
both total cholesterol and LDL-C. Six guidelines (9, 20, 21, 24–26) 
indicate DNA testing of a child whose parent has a confirmed 
diagnosis of FH. One guideline (9) suggests performing DNA 
analysis even in the case of dead or unknown parents. For adults, 
five guidelines recommend genetic testing where individuals 
present with high total cholesterol or LDL-C levels (see Table 2) 
(20, 22–24, 27). Three guidelines (9, 20, 24) indicate a genetic test 
to confirm clinical diagnosis of FH and four guidelines (9, 20, 24, 
taBLe 1 | Characteristics of the guidelines.
Guidelines, year Organization responsible for 
guidelines development
country applied conflict of 
interests
aGRee ii overall 
assessment
Familial Hypercholesterolemia; screening, diagnosis and 
management of pediatric and adult patients, 2011 (23)
National Lipid Association (NLA) USA SCI 4
Familial Hypercholesterolemia: A Model of Care for  
Australasia, 2011 (21)
Familial Hypercholesterolemia  
Australasia Network Consensus  
Group (FHANCG)
Oceania EI 5
Management of Familial Hypercholesterolemia in Children  
and Young Adults: Consensus Paper Developed by a Panel 
of Lipidologists, Cardiologists, Paediatricians, Nutritionists, 
Gastroenterologists, General Practitioners and a Patient 
Organization, 2011 (25)
NA (Descamps) Belgium NA 5
Integrated guidance on the care of familial hypercholesterolemia 
from the International FH Foundation, 2014 (9)
International FH Foundation (IFHF) USA SCI 6
Linee guida cliniche per la prevenzione della cardiopatia  
ischemica nella ipercolesterolemia familiare: una patologia  
sotto-diagnosticata e sotto-trattata, 2014 (24)
Società Italiana Studio  
Aterosclerosi (SISA)
Italy NA 3
Identification and Treatment of Patients with Homozygous  
Familial Hypercholesterolaemia: Information and  
Recommendations from a Middle East Advisory  
Panel, 2015 (19)
NA (Al-Ashwal) Middle East SCI 5
Familial hypercholesterolemia: identification and  
management, 2016 (26)
National Institute for Health and  
Care Excellence (NICE)
UK NA 4
Guidelines for the Management of Dyslipidemia, 2016 (20) European Society of Cardiology and 
the European Atherosclerosis Society 
(ESC-EAS)
Europe EI 5
Taiwan lipid guidelines for high risk patients, 2017 (27) Taiwan Society of Lipids and 
Atherosclerosis (TSLA)
Taiwan EI 4
Guidelines for Management of Dyslipidemia and Prevention  
of Cardiovascular Disease, 2017 (22)
American Association of Clinical 
Endocrinologists and American  
College of Endocrinology (AACE-ACE)
USA EI 5
EI, editorial independence declared; FIP, funding by industrial partners reported; FPO, funding by external public organization reported; SCI, statement about conflict of interests of 
group members present; AGREE II, Appraisal of Guidelines for Research and Evaluation II.
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27) where there are clinical manifestations of FH (i.e., xanthoma 
and/or premature CHD/CVD). Six guidelines (9, 20, 23, 24, 26, 
27) recommend DNA testing in the case of family history of FH, 
while two guidelines (22, 23) indicate this even if the family his-
tory is only suggestive of FH or where there is a family history 
of xanthoma or premature CHD/CVD. Six guidelines (9, 20, 23, 
24, 26, 27) indicate the use of DNA testing for cascade screening. 
Only one guideline (19) suggests that genetic counseling should 
be offered to couples at risk of HoFH in their offspring. In consid-
eration that only about 80% of the tested patients results positive 
for a mutation in LDL-R, APOB, or PCSK9 gene, a negative test 
does not exclude the diagnosis of FH. Seven guidelines (9, 19, 
21, 23, 25, 26) specifically recommend to consider the patients 
negative to genetic test which fall within clinical criteria for a 
possible FH diagnosis.
management of Positive Patients
Table S2 in Supplementary Material describes the health-care 
pathways that should be provided to patients positive for HeFH 
and HoFH, grouped for adult patients, woman, and children. Due 
to the large number of recommendations, we report below only 
the most relevant ones (see Table S2 in Supplementary Material 
for a comprehensive list of recommendations in the guidelines).
Adults
Regarding non-pharmacological treatment, six guidelines (9, 21– 
24, 26) recommend counseling adult patients about lifestyle 
modification; three of them (23, 24, 26) suggest taking at least 
30 min of physical activity a day, while four (22–24, 26) advise 
patients to stop smoking and to achieve and maintain a healthy 
weight. Three guidelines (22, 23, 26) contain recommendations 
on nutrition habits. Six guidelines (9, 20, 22–24, 26) point out 
that all adult patients with HeFH should receive lipid-modifying 
drug treatment to reduce LDL-C; three guidelines (22, 23, 26) 
recommend statin therapy as the primary pharmacological 
means of achieving target LDL levels; and six guidelines (9, 
21–24, 26) recommend a combination therapy when LDL-C 
targets are not achieved. Four guidelines (9, 21, 22, 26) recom-
mend monitoring indicators of liver and kidney injury during 
pharmacological treatment. Three guidelines (9, 23, 26) suggest 
LDL apheresis in patients under maximal drug therapy who still 
cannot achieve the LDL-C target; two guidelines (21, 23) rec-
ommend LDL apheresis when CVR is very high and LDL-C is 
above 160 mg/dl; and one guideline (23) suggests LDL apheresis 
in patients with high CVR and LDL-C above 200 mg/dl, or with 
LDL-C above 300 mg/dl even without other CVRs. Regarding 
LDL-C targets, five guidelines (9, 20, 23–25) recommend a 
taBLe 2 | Criteria to select individuals for genetic testing.
target population characteristics Recommendation Guidelines, year Strength of 
recommendation
General population DNA testing is not needed NLA, 2011 (23) NA
During acute illness or use of statins DNA testing is not indicated IFHF, 2014 (9) 2A
With an unlikely phenotypic diagnosis of FH DNA testing is not needed FHANCG, 2011 (21)
IFHF, 2014 (9)
C
1C
Children With cholesterol concentration >230 mg/dl  
or >95° percentile for age and sex
DNA testing is indicated SISA, 2014 (24) NA
With LDL concentration >150 mg/dl DNA testing is indicated ESC-EAS, 2016 (20) 1C
With low-density lipoprotein cholesterol (LDL-C) 
concentration >500 mg/dl in untreated patients
DNA testing is indicated Al-Ashwal, 2015 (17) NA
With LDL-C concentration >300 mg/dl in  
treated patients
DNA testing is indicated Al-Ashwal, 2015 (17) NA
With a parent with FH DNA testing is indicated FHANCG, 2011 (21)
Descamps, 2011 (25)
SISA, 2014 (24)
IFHF, 2014 (9)
ESC-EAS, 2016 (20)
NICE, 2016 (26)
A
1C
NA
1A
1C
NA
With parents deceased or unknown DNA testing is indicated IFHF, 2014 (9) 3B
With xanthoma or other physical findings of 
homozygous FH or at risk of homozygous FH
DNA testing is indicated by  
2 years of age
IFHF, 2014 (9) 2A
With suspected heterozygous FH DNA testing is indicated between  
the ages of 5 and 10
IFHF, 2014 (9)
ESC-EAS, 2016 (20)
2B
1C
With suspected homozygous FH DNA testing is indicated earlier  
than 5 years of age
ESC-EAS, 2016 (20) 1C
Based on age- and gender-specific LDL-C levels DNA testing is indicated ideally  
before puberty
IFHF, 2014 (9)
IFHF, 2014 (9)
2B
2C
Adult patients With cholesterol concentration >310 mg/dl  
or >95° percentile for age and sex
DNA testing is indicated SISA, 2014 (24) NA
With LDL concentration >190 mg/dl DNA testing is indicated ESC-EAS, 2016 (20)
NLA, 2011 (23)
NA
NA
With a known family history of FH DNA testing is indicated NLA, 2011 (23)
SISA, 2014 (24)
IFHF, 2014 (9)
ESC-EAS, 2016 (20)
NICE, 2016 (26)
TSLA, 2017 (25)
NA
NA
1A
1C
NA
1C
Pretesting counseling should be 
offered prior to any form of testing
IFHF, 2014 (9) 1A
With a known family mutation DNA testing for cascade screening  
is indicated
NLA, 2011 (23)
IFHF, 2014 (9)
SISA, 2014 (24)
ESC-EAS, 2016 (20)
NICE, 2016 (26)
TSLA, 2017 (25)
NA
1A
NA
1C
NA
1C
With a family history equivocal or only  
suggestive of FH
DNA testing is indicated NLA, 2011 (23) NA
With a family history of high cholesterol levels 
(total, non-HDL and LDL) consistent with FH
DNA testing is indicated AACE-ACE, 2017 (22) 4C
With a clinical diagnosis of FH DNA testing is indicated NLA, 2011 (23)
FHANCG, 2011 (21)
IFHF, 2014 (9)
NA
A
3A
With >5 points on the Dutch Score DNA testing is indicated SISA, 2014 (24) NA
With diagnosis of xanthoma or coronary heart 
disease (CHD) in the family history
DNA testing is indicated SISA, 2014 (24)
ESC-EAS, 2016 (20)
NA
1C
(Continued )
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target population characteristics Recommendation Guidelines, year Strength of 
recommendation
With a family history of unlikely diagnosis of FH DNA testing is not needed IFHF, 2014 (9) 1C
With severe hypercholesterolemia, tendon 
xanthoma, and/or premature CAD
DNA testing is indicated TSLA, 2017 (25) 1C
With CHD or cardiovascular disease before the 
age of 55 years for men and 60 years for women
DNA testing is indicated SISA, 2014 (24)
IFHF, 2014 (9)
ESC-EAS, 2016 (20)
NA
1A
1C
With premature ASCVD (MI or sudden death) 
before age of 55 years in father or other male first-
degree relative, or before age 65 years in mother 
or other female first-degree relative
DNA testing is indicated AACE-ACE, 2017 (22)
SISA, 2014 (24)
4C
NA
Couples where there is a risk of homozygous 
familial hypercholesterolemia in their offspring
Genetic counseling Al-Ashwal, 2015 (19) NA
taBLe 2 | Continued
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target of LDL-C < 100 mg/dl for patients without other CVR 
[or even with high CVR in the case of two guidelines (23, 24)], 
while one guideline (22) recommends a target of <70 mg/ml; 
five guidelines recommend a target LDL-C level of <70 mg/dl 
for patients with very high CVR (9, 20, 24, 27) or with clinical 
CVD (9, 24). The AACE/ACE guideline recommends keeping 
LDL-C levels below 70  mg/ml in patients with clinical CVD 
(22). For HoFH patients, five guidelines (9, 27) recommend 
LDL apheresis, while four guidelines (9, 19, 24, 27) recommend 
a target LDL-C level of <70 mg/dl where clinical CVD is present 
in these patients.
Women
Four guidelines (9, 21, 23, 26) recommend that lipid-modifying 
therapy should not continue during attempts to conceive (see 
Table S2 in Supplementary Material for timetable) and three of 
these (9, 21, 23) suggest offering prepregnancy counseling. Only 
two guidelines (9, 26) suggest offering female patients advice 
on contraception. Three guidelines (19, 23, 26) recommend the 
immediate interruption of statin treatment in the case of preg-
nancy, and two of them (19, 26) suggest offering an assessment of 
CHD risk. During breast feeding, five guidelines (9, 19, 21, 23, 26) 
recommend that statin therapy be suspended, and one guideline 
suggests the use of resins (26). Two guidelines (19, 23) suggest 
starting LDL apheresis, but only for HoFH women.
Children
For children, the recommendations for LDL-C target include 
<160 mg/dl (21), <135 mg/dl (20, 27), and <100 mg/dl (22). 
Five guidelines recommend beginning statin therapy between 
8 years (9, 20) and 10 years (21, 22, 26) of age, while four guide-
lines (9, 21, 22, 24) indicate to operate on lifestyle modifications 
and non-lipid risk factors. Three guidelines (9, 21, 26) also 
suggest routinely monitoring growth and pubertal develop-
ment. Four guidelines (21, 23–25) recommend commencing 
statin therapy from 10 years of age only when other CVRs are 
present, and three of these (21, 23, 24) indicate a target serum 
concentration of LDL-C lower than 130 mg/dl, while one (25) 
suggests a reduction of at least 30%. Seven guidelines (9, 19, 
21, 23, 24, 26, 27) contain specific recommendations for HoFH 
children: three (19, 23, 27) indicate a target LDL-C concentra-
tion in serum lower than 135 mg/dl and the use of statins as 
primary intervention with or without ezetimibe. Moreover, four 
guidelines (9, 21, 23, 24) recommend LDL apheresis, which in 
two cases (9, 19) should be started by the age of 5 years and not 
after the age of 8 years.
DiScUSSiON
In this systematic review of FH diagnosis and management 
guidelines, we focused on health-care pathways relating to 
genetic testing, both in referring individuals for testing and in 
recommending the correct preventive program triggered by test 
results and by familial or personal history. All the documents 
included in our search were evaluated using the AGREE II instru-
ment and were assessed as average-to-good practice guidelines. 
Although they were judged to be adequate in their clarity of the 
purpose and in the exposition of the recommendations, major 
concerns surround the poor description of the methodology 
used to produce the recommendations in most of the guidelines 
and the lack of information about the funding received and the 
conflicts of interest. Even when a conflict of interest is declared, 
there is no description on how it is handled. Where DNA testing 
for FH is recommended, our results show that testing is indicated 
for early detection of FH and is especially useful for identifying 
family members of carrier patients. Therefore, genetic testing 
can help physicians find possible FH cases using an integrated 
model of diagnosis.
Although the various guidelines propose different LDL-C 
cutoff levels, the majority agree on genetic testing of potential 
FH carriers after cholesterol level has been measured or other 
physical findings distinctive of FH have been observed or, in 
some cases, where family history is highly suggestive of FH. 
Moreover, genetic analysis is recommended if the DLCN 
score is >5 but additional criteria are needed to confirm FH 
diagnosis. Only the SBR criteria accept the presence of a DNA 
mutation as a definitive confirmation of FH, whereas the 
MEDPED criteria do not even take genetic testing into account 
in the FH diagnosis (28). Nevertheless, performing universal 
7Migliara et al. Genetic Testing Guidelines for FH
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screening of FH by genetic testing is not recommended in any 
of the guidelines, and one of them specifically advises against 
this possibility (23).
Once a causative mutation has been found in the index patient, 
DNA testing is highly indicated for first-degree family members, 
and possibly also for second- and third-degree relatives (9, 20, 
23, 24, 26, 27), an approach that is reported to be highly cost-
effective in finding FH patients (29, 30). Unfortunately, several 
authors in recent years have documented ineffective index case 
identification (15, 31, 32). In fact, available tools commonly used 
to aid FH diagnosis are believed to be insufficiently effective and, 
accordingly, a prognostic model to enhance FH detection in 
primary care has recently been developed (33). Furthermore, not 
finding a mutation does not rule out a diagnosis of FH, since the 
molecular techniques used are not 100% sensitive (13); this is in 
line with our results, which indicate that genetic analysis needs to 
be performed during the index patient assessment, when clinical 
criteria could underline a suspected FH case. It has been showed 
that the implementation of new techniques, such as the so-called 
NGS methodologies, may improve the detection rate of muta-
tion causative of FH (34) with lower cost and labor associated 
compared to DNA testing with conventional sequencing (35). 
Studies using these techniques will have to be taken into account 
in future updating of guidelines since the guidelines included in 
this review did not stated it explicitly.
With regard to health-care pathways followed after a genetic 
test result, this systematic review highlights the importance of 
genetic testing in distinguishing between heterozygous and 
homozygous patients. The various guidelines adopt different 
LDL-C levels as therapy targets, but they are similar within each 
patient group, with the homozygous group requiring stricter 
therapies and lower LDL-C target levels than the heterozygous 
group. However, the majority of guidelines agree on the definition 
of progressive interventions based on the patients’ genetic status 
and LDL-C levels: LDL apheresis is the treatment of choice to 
immediately reduce cholesterol level, and it is essential for the 
HoFH patients’ management where conventional lipid-lowering 
drug therapies are usually not sufficient.
It is particularly relevant that DNA analysis is performed in 
children where knowing their genetic status could determine 
the endorsement of aggressive therapeutic strategies at an earlier 
age to prevent premature CHD; especially, HoFH children are at 
very high risk of developing CVD and therefore they need to be 
managed efficiently since the beginning.
In conclusion, this study highlights the importance of DNA 
testing for the identification of FH patients and their carrier 
status at the earliest opportunity, which has significant benefits 
and implications with respect to mortality and morbidity. 
Currently, the best approach to ensure an effective patients’ 
management may be represented by a combined strategy of 
genetic testing and clinical approach to achieve the highest 
level of accuracy in the FH case identification. In addition, once 
a mutation causative of FH has been found in the index patient, 
the cascade genetic screening using DNA analysis is an excel-
lent tool to obtain an efficient detection of affected relatives. 
Indeed, while FH is a significant risk factor for CVD, it is also 
a treatable disorder whose inherited nature makes finding FH 
cases among family members of an index case essential. With 
this aim, further studies on how to improve detection of index 
cases could begin to address the need for early and effective 
management of FH patients and consequent arrest of the onset 
of premature CHD.
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